Fundamental analysis · SEC EDGAR · TTM through 31/03/2026

Fundamental analysis of Stryker Corp

SYK · NYSE · Surgical & Medical Instruments & Apparatus

Fundamental quality

REASONABLE

74

out of 100

Breakdown by area

I.GrowthEPS: 10.9% · Revenue: 10.2%
62
II.ProfitabilityNet margin: 13.2% · ROE: 14.5%
78
III.Financial healthNet debt/EBITDA: 1.8x · FCF: 18.1%
83

Source: SEC EDGAR · TTM through 31/03/2026

Reading the numbers

On average over recent years, earnings per share grew 10.9% a year and revenue advanced 10.2% a year.

On profitability, Stryker Corp shows a net margin of 13.2%, a gross margin of 63.8%, an ROE of 14.5%.

Its financial health shows net debt of 1.8 times its EBITDA and a free cash flow margin of 18.1%.

Adding up growth, profitability and financial strength, the traffic light gives SYK a fundamental quality of 74 out of 100. To also know whether it's cheap or expensive, the price is missing: enter it in the tool and you'll get the valuation verdict (P/E against its sector).

The thresholds are general and the system doesn't judge qualitative factors. See the full methodology and use this analysis as a first filter, never as a final decision.

Is Stryker Corp cheap or expensive?

That depends on the current price. Look it up, enter it in the tool and get the full valuation verdict (P/E against its sector).

Compute the valuation →
Advertising

Where to buy Stryker Corp?

Brokers you can use to invest in U.S. and European stocks.

Compare the brokers →